Actively Recruiting
Association of Genomic Polymorphisms With Cancer Cachexia in Subjects With Pancreatic Adenocarcinoma
Led by Wake Forest University Health Sciences · Updated on 2026-01-22
100
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
Sponsors
W
Wake Forest University Health Sciences
Lead Sponsor
A
Atrium Health Levine Cancer Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
Pancreatic adenocarcinoma (PDAC) often leads to cancer cachexia (CC), a serious condition involving loss of muscle mass and functional decline that cannot be reversed by normal nutritional support. This condition affects over 75% of patients with advanced PDAC, contributing to poor outcomes and increased mortality. Researchers are studying genetic differences, called genomic polymorphisms, that might be linked to cachexia specifically in PDAC patients to better understand this condition and improve future care. This observational pilot study involves 100 patients with locally advanced unresectable or metastatic PDAC. Researchers will collect blood or cheek swab samples during routine clinic visits to analyze genetic markers and clinical data such as body weight, muscle loss seen in imaging, and lab test results. They will also consider factors like disease stage, cancer treatments received, and locations of metastases to understand their impact on cachexia. Participants will provide informed consent and samples that will be stored and analyzed anonymously. Personal health information will be protected and linked to genetic data only in a deidentified way. The study will measure the presence and severity of cancer cachexia over about 3 months, as well as long-term outcomes like muscle loss, survival rates, and disease progression over up to 3 years. This research aims to identify biomarkers that could help diagnose or treat cachexia in PDAC patients.
CONDITIONS
Brief Title
Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent and HIPAA authorization for personal health information release
- Male or female patients aged 18 years or older at the time of consent
- Histological or cytological confirmation of pancreatic adenocarcinoma with locally advanced unresectable or metastatic disease
- Able to provide a blood or buccal sample
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 3 years
Participants who undergo routine care are observed with specimen collection during standard clinic visits to analyze genomic polymorphisms and other clinical factors related to cancer cachexia.
Specimens may be collected during any standard of care clinic visit after screening and confirmation of eligibility
Trial Site Locations
Total: 2 locations
1
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Actively Recruiting
2
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27103
Actively Recruiting
Research Team
C
CynDavia McKoy
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here